TNFRSF17 and synovial sarcoma: Our integration of hydroxychloroquine with SS-1 as a potential SS treatment was found to significantly increase the Schirmer’s test values for both eyes, and tended to decrease OSDI scores, increase sialoscintigraphy excretion results, and regulate the serum levels of Th17-related pathway cytokines, BAFF, and BCMA.